Structure-Guided Identification of Resistance Breaking Antimalarial N-Myristoyltransferase Inhibitors
- Francis Crick Inst., London (United Kingdom); Imperial College, London (United Kingdom)
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA (United States); UCB Pharma, Bainbridge Island, WA (United States)
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA (United States); Seattle Children’s Research Inst., Seattle, WA (United States)
- Columbia Univ. Medical Center, New York, NY (United States)
- Imperial College, London (United Kingdom)
- Francis Crick Inst., London (United Kingdom)
- GlaxoSmithKline, Stevenage, Hertfordshire (United Kingdom)
- Medicines for Malaria Venture, Geneva (Switzerland)
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA (United States); Seattle Children’s Research Inst., Seattle, WA (United States); Novo Nordisk Research Center, Seattle, WA (United States)
- GlaxoSmithKline, Stevenage, Hertfordshire (United Kingdom); GSK Medicines Research Centre, Stevenage (United Kingdom). Crick–GSK Biomedical LinkLabs
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA (United States); Seattle Children’s Research Inst., Seattle, WA (United States); Univ. of Washington, Seattle, WA (United States)
The attachment of myristate to the N-terminal glycine of certain proteins is largely a co-translational modification catalyzed by N-myristoyltransferase (NMT), and involved in protein membrane-localization. Pathogen NMT is a validated therapeutic target in numerous infectious diseases including malaria. In Plasmodium falciparum, NMT substrates are important in essential processes including parasite gliding motility and host cell invasion. Here, we generated parasites resistant to a particular NMT inhibitor series and show that resistance in an in vitro parasite growth assay is mediated by a single amino acid substitution in the NMT substrate-binding pocket. The basis of resistance was validated and analyzed with a structure-guided approach using crystallography, in combination with enzyme activity, stability, and surface plasmon resonance assays, allowing identification of another inhibitor series unaffected by this substitution. We suggest that resistance studies incorporated early in the drug development process help selection of drug combinations to impede rapid evolution of parasite resistance.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- Cancer Research UK; UK Medical Research Council; Wellcome Trust; Medicines for Malaria Venture; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); US Department of Health and Human Services (HHS)
- Grant/Contract Number:
- HHSN272201700059C; 1R21AI137815-01
- OSTI ID:
- 1544855
- Journal Information:
- Cell Chemical Biology, Vol. 26, Issue 7; ISSN 2451-9456
- Publisher:
- Cell Press - ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Web of Science
Similar Records
Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity
Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis